Annual General Meeting 2024

The Annual General Meeting 2024 took place on Wednesday, March 13, 2024, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark.

To replay the webcast of the Annual General Meeting, please use one of the following links:

Webcast (English)

Webcast (Danish)

Please click on the links below for information concerning Genmab A/S’ Annual General Meeting 2024.

 Shareholder letter
 Notice of Annual General Meeting 2024 with agenda, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Remuneration Policy
 Register online or use the registration form
 Submit proxy or postal vote online or use the form to submit proxy or postal vote
 2023 Annual Report of Genmab A/S
 2023 Compensation Report

The total number of voting rights and total share capital per February 15, 2024, is:

Total Number of Voting Rights: 66,074,535
Total Share Capital: 66,074,535

Questions regarding registration to participate may be directed to Euronext Securities at tel. no. (+45) 43 58 88 94 or [email protected].

Investor inquiries

  • Andrew Carlsen

    Vice President,
    Head of Investor Relations

    Telephone: +45 3377 9558

    Carl Jacobsens Vej 30
    2500 Valby

  • We process your personal data in accordance with applicable rules. Please click here to read our Privacy Policy.

    Please note that Genmab A/S, as a general rule, no longer sends the calling to Annual General Meetings by postal mail. If you wish to receive the invitation to future Annual General Meetings via e-mail, please register your e-mail address at the InvestorPortal. If you do not have access to an e-mail address, please contact Euronext Securities at: (+45) 43 58 88 66.

  • Who we are

    Read about Genmab’s purpose, core values and key accomplishments

    Learn more

  • Turning insights into medicine

    See the results of innovation that is rooted in science

    Explore the pipeline

  • Innovation for the future

    We are developing next-generation technologies

    See our technologies

You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.